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patients by the presence of 0-1 or 2-3 risk factor, the 2-year 
actuarial FFDP was 100% and 49% respectively (p=0,01, Fig 1). 
 
 
 
Conclusion: Although with a small cohort and a limited 
follow-up, these results seem to suggest that radical dose RT 
to all localization of disease is a valid approach in osseous 
OPC patients in association with ADT, also considering the 
low toxicity profile. Our predictive model aiming at 
identifying which patients may benefit of this kind of 
treatment seems to show that the ideal candidate could be a 
previously operated patient, with a iPSA≤24,2 ng/ml and with 
only one bone metastasis. 
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Purpose or Objective: Late rectal toxicity (LRT) is one of the 
main limitations of external radiotherapy (RT) for prostate 
cancer (PC). Purpose of this study was to evaluate the impact 
of various parameters on LRT, in a large cohort of patients 
undergoing radical or adjuvant RT in a series of clinical trials. 
 
Material and Methods: 597 patients were selected (median 
age: 70 years; range: 43-88; NCCN risk class: 59 low, 199 
intermediate, 339 high). Impact on grade ≥2 (RTOG) LRT of a 
series of parameters was analysed: previous radical 
prostatectomy, RT technique, type and duration of any 
adjuvant hormone therapy, RT dose and fractionation, acute 
rectal toxicity. LRT free survival curves were estimated 
according to the Kaplan Meier method. Univariate analysis 
was performed using log-rank test. Multivariate analysis was 
performed using "Cox's proportional hazard models". 
 
Results: Table 1 shows the results of the analysis. Overall, 
grade > 2 LRT free survivals was respectively 89.5% and 84.9% 
at 2 and 5 years. At univariate analysis only acute rectal 
toxicity was significantly related to LRT (p <0.001) while 
there was a negative trend in patients receiving adjuvant 
hormone therapy, especially with LH-RH analogues. 
Multivariate analysis confirmed only the correlation between 
acute rectal toxicity and LRT (p: 0.006). 
 
 
 
Conclusion: The results of this analysis showed no correlation 
between treatment parameters and LRT. This unexpected 
result is likely to be related to the use of modulated RT 
techniques in the majority of patients and to the distribution 
of the analysed parameters. For example, patients who have 
previously undergone radical prostatectomy, or treated with 
a hypofractionated regimen, generally received a lower total 
dose. The close correlation between acute and late toxicity 
seems to confirm the existence of a "consequential late 
toxicity" in radiation-induced damage to the rectum. This 
seems to suggest the utility of close endoscopic monitoring in 
the follow-up of patients with severe acute rectal toxicity. 
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Purpose or Objective: To report long term clinical outcomes 
in prostate cancer patients (pts) treated with IGRT Moderate 
Hypofractionated Simultaneous integrated boost (SIB) by 
Tomotherapy in a phase I-II study. 
 
Material and Methods: Between 2005 and 2011, 211pts were 
treated with IGRT Moderate Hypofractionated SIB in a phase 
I-II study . A subgroup of 128 pts ( 55 low- risk[LR], 33 
intermediate- risk [IR] and 40high-risk[HR]) with 5 years 
minimum follow up were considered for this analysis. IR and 
HR pts received 51,8 Gy on pelvic lymph-nodes (LN) and 
concomitant SIB to prostate up to 74,2Gy in 28 fr; LR pts 
were treated to the prostate to 71,4Gy in 28fr. Androgen 
deprivation (AD) was delivered to 27% LR/57% IR/87% HR pts 
for a median time of 12.5, 13.7 and 15,5 months (m) 
respectively. Biochemical relapse free (bRFS) survival 
(Phoenix definition), cancer-specific (CCS) and overall 
survival (OS) actuarial curves were assessed. Selected 
clinical/dosimetry variables were tested as potential 
predictors of GI /GU toxicity and of BCR/CCS/OS (Cox test) . 
 
